293PD_PRRibociclib (RIBO) + letrozole (LET) in male...

Annals of Oncology 2018 / 10 Vol. 29; Iss. suppl_8

293PD_PRRibociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial

Zamagni, C, Campone, M, Kudryavcev, I, Brown-Glaberman, U, Cottu, P H, Ring, A, Lu, J, Martín, M, De Laurentiis, M, Zhou, K, Wu, J, Menon, L, Azim, H A
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy424.012
Date:
October, 2018
File:
PDF, 82 KB
english, 2018
Conversion to is in progress
Conversion to is failed